REC601-HPV Bivalent (Type 16/18) Vaccine

We are developing a bivalent HPV vaccine candidate, namely REC601, targeting HPV types 16 and 18, which are the main cause for a majority of cervical cancer cases. Currently, we have completed data evaluation and analysis on the phase I trial in China. The phase I trial data showed that REC601 has a favorable safety profile and an immunogenicity profile in healthy females aged 9 to 45.We will adopt a more reasonable follow-up development strategy by taking into account market demand and relevant regulatory guidance.